the invention relates to a combination of treatments , more particularly a combination treatment for hiv - 1 infection . the present invention is directed to the use of bryostatin - 1 and their natural and synthetic derivatives for aids therapy , in particular to the use of bryostatins in combination with other active drugs such as histone deacetylases inhibitors and anti - retrovirals , for the treatment of hiv - 1 latency . according to the present invention , we provide a combination therapy for the treatment of hiv - 1 latency which employs bryostatin - 1 and one of the following hdac inhibitors ; valproic acid , butyrate derivatives , hydroxamic acids and benzamides . while hdaci can be used in continuous dosing protocol , bryostatins can be used following a cyclical dosing protocol . bryostatins can be formulated in pharmaceutical acceptable carriers including nanoparticles , phospholipids nanosomes and / or biodegradable polymer nanospheres . this combination therapy needs to be used in patients treated with antiretroviral therapy .